Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2015 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Announces Third Quarter 2015 Financial Results

BERKELEY, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the third quarter and nine months ended September 30, 2015. Net income...
November 20, 2015 08:40 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology

CAMBRIDGE, Mass., Nov. 20, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") today presented an update and new data supporting its glioblastoma multiforme ("Glioblastoma" or "GBM")...
November 20, 2015 08:00 ET | Source: Chinook Therapeutics, Inc.

Aduro Biotech Europe’s Chief Scientific Officer, Andrea Van Elsas, Ph.D. Featured as Keynote Speaker on Immunomodulatory Antibodies at ESMO Symposium on Immuno-Oncology 2015

BERKELEY, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a clinical-stage immunotherapy company, today announced the presentation of an overview of novel antibody and...
November 18, 2015 03:21 ET | Source: EQS Group AG

DGAP-News: MOLOGEN to present two posters at ESMO IO 2015 (news with additional features)

DGAP-News: MOLOGEN AG / Key word(s): Conference MOLOGEN to present two posters at ESMO IO 2015 (news with additional features) 18.11.2015 /...
November 04, 2015 07:00 ET | Source: ArQule, Inc.

ArQule Reports Third Quarter 2015 Financial Results

Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., Nov. 04, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced its financial results for the third quarter of...
November 03, 2015 09:00 ET | Source: Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

ROCKVILLE, Md., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
November 03, 2015 07:00 ET | Source: Lumos Pharma, Inc.

NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2015 Financial Results

AMES, Iowa, Nov. 03, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
November 02, 2015 16:01 ET | Source: NanoString Technologies, Inc.

NanoString Technologies Releases Financial Results for Third Quarter of 2015

Record Revenue of $15.7 Million Driven by Strong Consumables Demand Expanded Solutions in Precision Oncology, including nCounter SPRINT and 3D Biology, Strengthen Company's Position at Center of...
October 30, 2015 05:30 ET | Source: ARMO BioSciences

ARMO BioSciences Presents Positive Phase 1 Trial Results of AM0010 at Upcoming Medical Conferences

REDWOOD CITY, CA--(Marketwired - Oct 30, 2015) - ARMO BioSciences, Inc., a leading developer of immuno-oncology therapeutics, today announced that positive results from an ongoing Phase 1 clinical...
October 15, 2015 16:00 ET | Source: ArQule, Inc.

ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 and Next Generation AKT Inhibitor ARQ 751 in Oncology

Pre-Clinical Data Supports the Use of AKT1 and PI3K Mutations as Biomarkers for the Company’s AKT Inhibitors BURLINGTON, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today...